Why carry out this study?

Clinical differences between sonidegib and vismodegib in patients with locally advanced basal cell carcinoma or metastatic basal cell carcinoma remain unclear as there are no head-to-head clinical trials comparing these Hedgehog inhibitors

This post hoc analysis describes the time to onset and severity of treatment-emergent adverse events in patients in the BOLT pivotal trial for sonidegib and patients in the expanded access, open-label study for vismodegib

What was learned from this study?

Patients treated with sonidegib had a later median time to onset for all adverse events than patients treated with vismodegib, with the exception of fatigue and weight decrease

Adverse events with both treatments were primarily low grade (grade ≤2)

This post hoc analysis described differences between sonidegib and vismodegib furthering the understanding of trends relative to their safety profiles; additional studies are needed to confirm the relevance of these findings